Replication data for: The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
Principal Investigator(s): View help for Principal Investigator(s) Mark Duggan; Fiona Scott Morton
Version: View help for Version V1
Name | File Type | Size | Last Modified |
---|---|---|---|
data | 10/11/2019 02:36:PM | ||
LICENSE.txt | text/plain | 14.6 KB | 10/11/2019 10:36:AM |
Project Citation:
Duggan, Mark, and Scott Morton, Fiona. Replication data for: The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. Nashville, TN: American Economic Association [publisher], 2010. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-11. https://doi.org/10.3886/E112338V1
Project Description
Summary:
View help for Summary
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical prices, the government contracted with private insurers to provide drug coverage. Theory suggests that additional insured consumers will raise the optimal price of a branded drug, while the insurer's ability to move demand to substitute treatments may lower prices. We estimate the program's effect on the price and utilization of pharmaceutical treatments. We find that Part D enrollees paid substantially lower prices than while uninsured, and increased their utilization of prescription drugs. We find relative price declines only for drugs with significant therapeutic competition. (L18, L11, L65)
Scope of Project
JEL Classification:
View help for JEL Classification
I18 Health: Government Policy; Regulation; Public Health
L11 Production, Pricing, and Market Structure; Size Distribution of Firms
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
I18 Health: Government Policy; Regulation; Public Health
L11 Production, Pricing, and Market Structure; Size Distribution of Firms
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
Related Publications
Published Versions
Report a Problem
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.